Curaleaf buys Greenroots for US$875M to expand footprint across U.S.

Production isn't everything when examining cannabis stocks, but it's probably the first factor a lot of investors consider when beginning to analyze the space. There's long been the idea that higher levels of production will lead to better profitability, which isn't always the case.

EV/sales is ratio that is used by investors to help value companies by comparing the enterprise value of the company to its annual sales. This provides investors with a quantifiable metric that shows how much it will cost to purchase a company’s sales. A lower EV/sales multiple could indicate that the Company is undervalued. Today we have weeded out four Canadian cannabis stocks that are considered undervalued on an EV/sales basis. For reference, the stocks were chosen from a list of 113 Canadian cannabis stocks that had an average EV/sales ratio of 20.3x in 2019E and 5.9x in 2020E.

Canopy Growth is the largest marijuana company in the world by market cap. The firm dominates the Canadian market and racks up revenues that outperform that of any of its peers.

Canopy Growth may be one of the better investment options for those looking to profit from the marijuana craze, but one of the firm’s subsidiaries, namely Canopy Rivers (TSXV:RIV), could be an interesting option to consider as well. 

It’s been almost a year since marijuana was legalized nationwide, and there’s been pandemonium in the industry. After Health Canada began investigating CannTrust Holdings (TSX:TRST)(NYSE:CTST) for unlicensed cultivation, the small-cap producer suspended all sales, sending shock waves across the entire sector. CannTrust had previously been one of the few consistently profitable weed companies in both net and operating terms, making its current troubles a blow to an industry that is facing increasing heat for mounting losses and poor cost control.

Marijuana stocks remain under considerable pressure, as a range of calamities and fears that the global legal marijuana market won’t be as large as originally claimed weigh on their value.

These growing concerns have done little to curb the rash of impending initial public offerings (IPOs) for the legal cannabis industry, which is being touted as a superior alternative to pharmaceuticals, liquor, and tobacco.

In a decade's time, the marijuana industry is going to be a veritable giant. Depending on your preferred source, Wall Street firms are projecting anywhere from $50 billion in annual worldwide sales to as much as $200 billion in cannabis and cannabinoid sales per year around the globe. These pie-in-the-sky sales figures have been a driving force behind pot stock valuations for years.

On Monday, OrganiGram (OGI) reported its third-quarter earnings. Following the company’s earnings, we reported how it performed in the third quarter. To learn more, read OrganiGram’s Third-Quarter Earnings.

Form factors

Interestingly, OrganiGram stressed that the growth would be heavily driven by retail stores opening in Ontario and Quebec. The company stated that legalizing edibles and derivative products would also drive growth. Derivative products including oil, vaporizers, and beverages like cannabis tea will drive cannabis sales.

https://technical420.com/cannabis-article/5-canadian-licensed-producers-you-can-trust/#

Canadian Licensed Producers (LPs) have once again become a focal point of the cannabis industry after recently coming under considerable pressure, a trend that we have been closely monitoring.

During the last month, Canadian LPs have been trending lower and we believe that this weakness is the result of two primary developments: 1) The firing of Bruce Linton as the CEO of Canopy Growth (WEED.TO) (CGC), and 2) The non-compliance notice issued by Health Canada to CannTrust Holdings (TRST.TO) (CTST).

Last year, Canopy Growth (TSX:WEED)(NYSE:CGC) announced the acquisition of the leading Colombian medical marijuana company, Spectrum Cannabis. According to an SEC filing dated February 14, 2019, Spectrum Cannabis owns 126 hectares of land on which Canopy Growth may cultivate legal marijuana.

Spectrum Cannabis began as a family-owned medical cannabis company in Colombia following medical marijuana’s legalization in 2016. Post-acquisition, Bibiana Rojas, the daughter of Spectrum’s founders, bravely manages Canopy Growth’s Colombian operations, a critical regional production hub.